Enara Bio to present progress in Dark Antigen™ research at upcoming Neoantigen-Based Therapies Summit
Enara Bio, a biotechnology company leveraging its proprietary T-cell/T-cell receptor (TCR) discovery and Dark Antigen™ platforms to deliver targeted cancer immunotherapies, will present at the 5th Neoantigen Based Therapies Summit on November 5.
At this virtual event, Dr. Kevin Pojasek, President and CEO of Enara Bio, will provide an overview of the company’s work with Dark Antigens and Dark Antigen reactive T-cells, discovered through its proprietary EDAPT™ platform. EDAPT combines transcriptomics, immunopeptidomics and state-of-the-art immunology to discover and validate novel Dark Antigens with which to deliver a pipeline of novel cancer immunotherapies.
Dr. Pojasek will also touch on Enara’s efforts to target the HLA-like receptor MR1, which has previously been shown to present unconventional ligands in a cancer-specific manner. Due to its ubiquitous and monomorphic expression, MR1 constitutes a promising target for potential off-the-shelf, pan-cancer, pan-population immunotherapies.
The presentation will take place on November 5 at 3.15pm EST. For more details and to register please visit neo-antigen.com.